Revolutionary Weight Loss Approach: ESG and GLP-1 Drugs Combined

 
A transformative study* has shown that combining Endoscopic Sleeve Gastroplasty (ESG) with GLP-1 receptor agonist drugs, such semaglutide, delivers superior weight loss results compared to ESG alone. This innovative combination is changing the landscape of obesity treatment.

 

What Are ESG and GLP-1 Drugs?

• Endoscopic Sleeve Gastroplasty (ESG) : A non-surgical procedure that reduces stomach size using an endoscope and sutures. This helps you feel full faster and eat less, promoting weight loss.
• GLP-1 Drugs: Medications like Semaglutide mimic a natural hormone to control appetite and blood sugar. These weekly injections slow digestion, curb hunger, and support sustained weight loss when paired with lifestyle changes.

 

Key Findings from the Study

• Enhanced Weight Loss: Patients who received both ESG and GLP-1 drugs achieved an impressive 23.7% total weight loss (TWL) within 12 months, significantly more than the 17.3% TWL achieved by those undergoing ESG alone.
• The Timing Advantage: Initiating GLP-1 therapy within six months of ESG maximized weight loss results, while starting later reduced effectiveness.

 

Why the Combination Works Better

The study highlights the complementary mechanisms of ESG and GLP-1 drugs:

• ESG reshapes the stomach, reducing its size and slowing digestion, which helps control portion sizes and enhances feelings of fullness.
• GLP-1 Drugs further boost these effects by regulating hunger hormones, slowing gastric emptying, and improving insulin response.

Together, these therapies create a powerful and sustained weight-loss strategy, offering results comparable to bariatric surgery but with less risk and downtime.
 
 

The Importance of Timing

The study emphasized the critical role of timing in achieving optimal results. Patients experienced the most significant weight loss when GLP-1 therapy was initiated during the first six months after ESG, aligning with the peak weight-loss phase of the procedure.
 
 

A Safer, Effective Alternative to Surgery

For individuals hesitant about invasive bariatric surgery, the ESG and GLP-1 combination provides a safer, minimally invasive option that delivers comparable outcomes. It’s a tailored approach that meets the needs of those seeking lasting weight-loss solutions.
 
 

Why This Matters

This research is a game-changer for individuals battling obesity. It offers a scientifically proven, personalized approach that not only addresses weight but also improves related health conditions such as diabetes and hypertension.
 
 

Take the Next Step

Bumrungrad International Hospital’s Digestive Disease Center is at the forefront of this innovative weight-loss approach. With a commitment to evidence-based care, our experts are ready to guide you through personalized treatment plans, combining the latest medical advances with compassionate care.

 

*Source: Efficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents

 

By Asst. Prof. Dr. Veeravich Jaruvongvanich, Gastroenterology and Hepatology